AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
View Patent ↗Compounds represented by the formula: and pharmaceutically acceptable salts thereof and prodrugs thereof; wherein R 1 is H, CH 3 , C 2 H 5 , C 3 H 7 R 2 is H, CH 3 , C 2 H 5 , C 3 H 7 , CH═CH 2 , CH 2 —OH, CH 2 F, CF 3 R′ 2 is H, OH, NH 2 , NH-alkyl, F, N 3 , OCH 3 , O—C(O)CH(NH 2 )alkyl R 3 is H, CH 3 , C 2 H 5 , C 3 H 7 R′ 3 is H, OH, NH 2 , NH-alkyl, F, N 3 , OCH 3 , O—C(O)CH(NH 2 )alkyl R 4 is H, CH 3 , C 2 H 5 , C 3 H 7 At least one of R 2 , R 3 , or R 4 has to be other than H, when X═NH in B R 6 is H, CH 3 , C 2 H 5 , R 7 is selected from H, alkyl, alkenyl, aryl, acyloxyalkyl, and pivaloyloxyalkyl, aminoacids, CH 2 CH 2 SC(O)alkyl; and B is represented by the following structure: X is independently NR 6 , O, S, R 8 and R 9 independently is H, NH 2 , OH, SH, F, Cl, Br, I, aryl, heterocycle, alkyl, alkene, alkyne, S-alkyl, S-aryl, S(O)-alkyl, SO 2 -alkyl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, NH-alkyl, NH-aryl, N(alkyl) 2 , N(aryl) 2 , O-alkyl, O-aryl, O-heterocycle, NH-(CH 2 ) n -aryl, NH—C(O)-alkyl, NH—C(O)-aryl are useful for inhibiting viral RNA polymerases and treating patients suffering from diseases caused by various RNA viruses.
1. A compound or a pharmaceutically acceptable salt thereof represented by the formula:
wherein,
R 1 is H, CH 3 , C 2 H 5 , or C 3 H 7 ;
R 2 is H, CH 3 , C 2 H 5 , C 3 H 7 , CH═CH 2 , CH 2 —OH, CH 2 F, or CF 3 ;
R′ 2 is OH, NH 2 , NH-alkyl, F, N 3 , OCH 3 , or O—C(O)CH(NH 2 )alkyl;
R 3 is H, CH 3 , C 2 H 5 , or C 3 H 7 ;
R′ 3 is H, OH, NH 2 , NH-alkyl, F, N 3 , OCH 3 , or O—C(O)CH(NH 2 )alkyl;
R 4 is H, CH 3 , C 2 H 5 , or C 3 H 7 ;
at least one of R 2 , R 3 , and R 4 has to be other than H, when X═NH in B
R 6 is H or
R 7 is selected from H, alkyl, alkenyl, aryl, acyloxyalkyl, and pivaloyloxyalkyl, aminoacids, and CH 2 CH 2 SC(O)alkyl;
B is represented by the following structure:
X is NR 6 , O, or S;
R 8 is H, NH 2 , OH, SH, F, Cl, Br, I, aryl, heterocycle, alkyl, alkene, alkyne, S-alkyl, S-aryl, S(O)-alkyl, SO 2 -alkyl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, NH-alkyl, NH-aryl, N(alkyl) 2 , N(aryl) 2 , O-alkyl, O-aryl, O-heterocycle, NH-(CH 2 ) n -aryl, NH—C(O)-alkyl, or NH—C(O)-aryl; and
R 9 is H, NH 2 , OH, SH, F, Cl, Br, I, aryl, heterocycle, alkyl, alkene, alkyne, S-alkyl, S-aryl, S(O)-alkyl, SO 2 -alkyl, SO 2 NH 2 , SO 2 NH-alkyl, SO 2 NH-aryl, NH-alkyl, NH-aryl, N(alkyl) 2 , N(aryl) 2 , O-alkyl, O-aryl, O-heterocycle, NH-(CH 2 ) n -aryl, NH—C(O)-alkyl, or NH—C(O)-aryl.
2. A compound selected from the group consisting of:
(2R,3R,4S,5S)-2-(Hydroxymethyl)-5-(4-(methoxyamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrimidine-3,4-diol,
(2R,3R,4S,5S)-2-(Hydroxymethyl)-5-(4-(1-methylhydrazinyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidine-3,4-diol,
(2S,3S,4R,5R)-2-(4-(1-Ethylhydrazinyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrimidine-3,4-diol,
(2S,3S,4R,5R)-2-(4-(Dimethylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrromidine-3,4-diol,
(2R,3R,4R)-3,4-Bis(benzyloxy)-2-(benzyloxymethyl)-4-methylpyrrolidine,
(2R,3R,4S)-3,4-Bis(benzyloxy)-2-(benzyloxymethyl)-4-methylpyrrolidine,
(2R,3R,4S)-2-(Hydroxymethyl)-4-methylpyrrolidine-3,4-diol hydrochloride,
(3aS,6R,6aR)-6-((tert-Butyldimethylsilyloxy)methyl)-2,2,3a-trimethyl-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyrrole,
(2S,3S,4R,5R)-2-(4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol,
(2S,3S,4R,5R)-2-(4-Aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol,
(2S,3S,4R,5R)-2-(4-Aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol,
7-((2S,3S,4R,5R)-3,4-Dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl)-2-(methylthio)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one,
7-((2S,3S,4R,5R)-3,4-Dihydroxy-5-(hydroxymethyl)-3-methylpyrrolidin-2-yl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one,
(2S,3S,4R,5R)-2-(4-Aminothieno[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol,
(2S,3S,4R,5R)-2-(4-Aminofuro[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, and
((2S,5R)-5-(4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidin-2-yl)methyl dihydrogen phosphate.
3. A pharmaceutical composition comprising a compound according to any one of claims 1 and 2 , and a pharmaceutical carrier.
4. A method for inhibiting RNA viral polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
5. A method for inhibiting HCV polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
6. A method for inhibiting HBV polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
7. A method for inhibiting Rhino polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
8. A method for inhibiting small pox polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
9. A method for inhibiting Ebola polymerase comprising administering to a patient in need thereof in an effective amount of at least one compound according to any one of claims 1 and 2 .
10. A method for inhibiting polio virus polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
11. A method for inhibiting West Nile polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
12. A method for inhibiting Coxsackie A polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
13. A method for inhibiting Coxsackie B polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
14. A method for inhibiting Echo polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 .
15. A method for treating a patient suffering from an RNA viral infection comprising administering said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
16. A method for treating a patient suffering from HCV infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
17. A method for treating a patient suffering from HBV infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
18. A method for treating a patient suffering from a Rhino viral infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
19. A method for treating a patient suffering from a small pox viral infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
20. A method for treating a patient suffering from a Ebola viral infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
21. A method for treating a patient suffering from a polio viral infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
22. A method for treating a patient suffering from a West Nile viral infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
23. A method for treating a patient suffering from a Coxsackie A viral infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
24. A method for treating a patient suffering from a Coxsackie B viral infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
25. A method for treating a patient suffering from an Echo viral infection comprising administering to said patient an effective amount of at least one compound according to any one of the claims 1 and 2 .
26. A method for inhibiting in a patient RNA viral polymerase comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 and at least one further therapeutic agent related from the group consisting of interferon (IFN), interferon α-2a, interferon α-2b, consensus interferon (CIFN), ribavirin, amantadine, rimantadine, interleukine-12, ursodeoxycholic acid (UDCA), and glycyrrhizin, and inhibiting RNA viral polymerase.
27. The method of claim 26 wherein the RNA viral polymerase comprises at least one member selected from the group consisting of HCV polymerase, HBV polymerase, Rhino polymerase, small pox virus polymerase, Ebola virus polymerase, Coxsackie A and B polymerase, Echo polymerase and west Nile virus polymerase.
28. A method for treating RNA viral infection comprising administering to a patient in need thereof an effective amount of at least one compound according to any one of claims 1 and 2 and at least one further therapeutic agent chosen from interferon (IFN), interferon α-2a, interferon α-2b, consensus interferon (CIFN), ribavirin, amantadine, rimantadine, interleukine-12, ursodeoxycholic acid (UDCA), and glycyrrhizin.
29. The method of claim 28 wherein the RNA viral infection comprises at least one member selected from the group consisting of HCV, HBV, Coxsackie A, Coxsackie B, Echo, Rhino viral infection, small pox viral infection, Ebola viral infection, polio viral infection and West Nile viral infection.